Invitae Corp
Change company Symbol lookup
Select an option...
NVTA Invitae Corp
BAC Bank of America Corp
KVHI KVH Industries Inc
BHC Bausch Health Companies Inc
ANPC AnPac Bio-Medical Science Co Ltd
TREX Trex Company Inc
VIVO Meridian Bioscience Inc
WASH Washington Trust Bancorp Inc
AWF AllianceBernstein Global High Income Fund Inc.
AVK Advent Convertible & Income Fund
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.

Price
Delayed
$45.26
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)

Today's volume of 1,622 shares is on pace to be much lighter than NVTA's 10-day average volume of 2,659,962 shares.

1,622

Company Profile

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.

Valuation Ratios

Price/Earnings (TTM)
--
Price/Sales (TTM)
34.61x
Price/Book (MRQ)
12.80x
Price/Cash Flow (TTM)
--
TTM = Trailing Twelve Months
MRQ = Most Recent Quarter

Price Performance

Historic Growth and Share Detail

Historic Growth

Annual growth, past 5 years
EPS
Revenue
Dividend No Regular Dividend is paid
 

Short Interest

September 2020
Current Month
21.3M
Previous Month
21.5M
Percent of Float
16.29%
Days to Cover
6.5010 Days

Share Information

NVTA is in a share class of common stock
Float
176.1M
Shares Outstanding
178.3M
Institutions Holding Shares
297
66.89%

Financial Statements

Balance sheet

Values displayed are in millions.

Income statement

Values displayed are in thousands.

Cash flow

Values displayed are in thousands.

Company Officers

  • Sean E. GeorgeChmn.
  • Shelly D. GuyerCFO
  • Kenneth KnightCOO
  • Robert F. WernerCAO
  • Thomas R. BridaCounsel

Address

Insider Trading

During the most recent quarter, 294K shares were sold in insider trading.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Insider trading information report provided by Copyright © 2020. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.